MICROPARTICLES CONTAINING BUPROPION
This disclosure relates to microparticles containing bupropion, e.g., microparticles having a particle diameter of about 50 μm to about 100 μm. These microparticles may be included in pharmaceutical compositions and/or dosage forms for treatment of various disease, such as depression.
1 . A microparticle comprising bupropion, wherein the microparticle has a particle diameter of about 50 μm to about 100 μm.
2 . The microparticle of claim 1 , wherein the particle diameter is determined by laser diffraction, and wherein the bupropion is bupropion hydrochloride.
3 . The microparticle of claim 1 , wherein bupropion comprises about 30% to about 35% of the weight of the microparticle.
4 . A dosage form comprising microparticles containing bupropion, wherein at least about 80% of the microparticles have a particle diameter of about 1 μm to about 300 μm.
5 . The dosage form of claim 4 , wherein the particle diameter is determined by laser diffraction, and wherein the bupropion is bupropion hydrochloride.
6 . The dosage form of claim 4 , wherein the median microparticle diameter is about 50 μm to about 100 μm as determined by laser diffraction.
7 . The dosage form of claim 6 , wherein the 10 th percentile of microparticle diameter is about 1 μm to about 30 μm as determined by laser diffraction.
8 . The dosage form of claim 6 , wherein the 90 th percentile of microparticle diameter is about 200 μm to about 300 μm as determined by laser diffraction.
9 . The dosage form of claim 6 , wherein the 90 th percentile of microparticle diameter is about 2 times to about 6 times the median microparticle diameter as determined by laser diffraction.
10 . The dosage form of claim 6 , wherein the median particle diameter is about 2 times to about 50 times the 10 th percentile of microparticle diameter as determined by laser diffraction.
11 . A pharmaceutical composition comprising microparticles containing bupropion, wherein at least 80% of the microparticles have a particle diameter of about 1 μm to about 300 μm.
12 . The pharmaceutical composition of claim 11 , wherein the particle diameter is determined by laser diffraction, and wherein the bupropion is bupropion hydrochloride.
13 . The pharmaceutical composition of claim 11 , wherein the microparticles containing bupropion have a median particle diameter of about 50 μm to about 100 μm as determined by laser diffraction.
14 . The pharmaceutical composition of claim 11 , wherein microparticles in the 10 th percentile based upon particle diameter have a diameter of about 1 μm to about 30 μm as determined by laser diffraction.
15 . The pharmaceutical composition of claim 11 , wherein microparticles in the 90 th percentile based upon particle diameter have a diameter of about 200 μm to about 300 μm as determined by laser diffraction.
16 . The pharmaceutical composition of claim 11 , wherein the 90 th percentile of microparticle diameter is about 2 times to about 6 times the median microparticle diameter as determined by laser diffraction.
17 . The pharmaceutical composition of claim 11 , wherein the median particle diameter is about 2 times to about 50 times the 10 th percentile of microparticle diameter as determined by laser diffraction.
18 . The pharmaceutical composition of claim 12 , further comprising a sustained release or controlled release polymer.